2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
22
Terminated
7
Recruiting
6
Unknown
3
Enrolling by invitation
2
Withdrawn
1
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Malignant Female Reproductive System Neoplasm
1
Interventions
Specimen Handling
34
Magnetic Resonance Spectroscopy
22
Biopsy
20
Cyclophosphamide
16
Nivolumab
10
Paclitaxel
9
Cisplatin
9
Gemcitabine
8
Bevacizumab
8
venetoclax
7
Vincristine
7
Prednisone
7
Doxorubicin
7
Azacitidine
7
pembrolizumab
6
Radiotherapy
6
Radiosurgery
6
Fluorouracil
6
Etoposide
6
Drug Therapy
6
Docetaxel
6
Taxes
5
Surgical Procedures, Operative
5
Rituximab
5
Oxaliplatin
5
Irinotecan
5
Everolimus
5
Capecitabine
5
fludarabine phosphate
4
fludarabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Enoxaparin
×
Clear all
NCT01356329
2016-05-13
Lovenox
National Guard Health Affairs
Phase 3
Suspended
150 enrolled